A universal vaccine to protect against multiple coronavirus variants
Official title: A Novel Multi-Epitope-Based Universal Vaccine Against Multiple Coronavirus Variants of Concern
Funded at Techimmune, LLC · NIH-10773626 · Data updated 2026-11-12
This study is testing a new vaccine designed to protect against different strains of the coronavirus, especially the ones that have changed and spread more easily, and it's for people who want to help find a way to stay safe from current and future variants.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Techimmune, LLC NIH-funded |
| Lab location | 1 site (Newport Beach, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 5R43AI174383-02 |
| Project ID | NIH-10773626 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals who are at risk of COVID-19 infection or those who have not yet been vaccinated.
✕Less likely to help
Patients who have already been vaccinated with a first-generation COVID-19 vaccine may not benefit directly from this research.
What this research studies
This research aims to develop a novel vaccine that targets various strains of the coronavirus, particularly those that have mutated and become more transmissible. The approach focuses on identifying and utilizing conserved antigens from the virus that can stimulate both B-cell and T-cell immune responses, which are crucial for long-lasting immunity. By moving beyond the traditional focus on the Spike protein, this vaccine seeks to provide broader protection against current and future variants of concern. Patients may be involved in trials to assess the vaccine's safety and effectiveness.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that provides lasting immunity against multiple coronavirus variants, potentially reducing the incidence of COVID-19.
How similar studies have gone: While there have been advancements in vaccine development for COVID-19, this approach of creating a universal vaccine targeting multiple variants is relatively novel and has not been extensively tested.
Where this research is happening
-
Techimmune, LLC
Newport Beach, United States Active
Researchers
- Principal investigator: Vahed, Hawa — Techimmune, LLC
- Study coordinator: Vahed, Hawa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.